Category: RESEARCH

INTERVIEW

Psychedelic Drugs ‘Far Exceed’ Cannabis Investment Potential (CNBC)

Editor | Curator - October 19, 2021

RESEARCH

Psychedelic Therapeutics Sector Outlook Released (Valhalla Ventures)

Editor | Curator - October 18, 2021

Psychedelic Investor Guide

2021 Psychedelic Investor Guide Released.

Editor | Curator - October 18, 2021

Report: Ehave Inc (EHVVF) Our Favorite Psychedelic Company

RESEARCH Editor | Curator - September 24, 2021

WE LOOKED FAR AND WIDE TO FIND OUR FAVORITE What exactly is a favorite? First what it isn’t. In early August our research team...

View Post

Subscribe for Free!

RESEARCH Editor | Curator - August 9, 2021

EXCELLENT CHOICE, SIR! AND CHEERS TO YOU FOR SUBSCRIBING Subscribe For Your Free Copy to the 2021 Psychedelic Investor Guide

View Post

Cybin (CLXPF CYBN) Gets $8.00 Price Target From H.C. Wainwright.

RESEARCH Editor | Curator - July 27, 2021

Advancing Multiple Psychedelics in Multiple Indications; Initiating With a Buy and $8 Price Target. REPORT

View Post

Most Popular

Psychedelic Drugs ‘Far Exceed’ Cannabis Investment Potential (CNBC)

INTERVIEW Editor | Curator - October 19, 2021

Shark Tank’s Kevin O’Leary, Wesana (WSNAF) CEO Daniel Carcillo and director at Mass General Hospital’s Center for the Neuroscience of Psychedelics Dr....

Psychedelic Therapeutics Sector Outlook Released (Valhalla Ventures)

RESEARCH Editor | Curator - October 18, 2021

Valhalla Ventures backs visionary founders at the forefront of social and technological movements that younger generations care about most.

2021 Psychedelic Investor Guide Released.

Psychedelic Investor Guide Editor | Curator - October 18, 2021

Institutional Analyst Inc. announced the release of the 2021 Psychedelic Investor Guide on Monday, October 18th. The Psychedelic Investor Guide is the...